Tom Frohlich - Chinook Therapeutics Chief Officer

Insider

Tom Frohlich is Chief Officer of Chinook Therapeutics
Age 47
Phone206 485 7241
Webhttps://www.chinooktx.com

Chinook Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.2682) % which means that it has lost $0.2682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5685) %, meaning that it created substantial loss on money invested by shareholders. Chinook Therapeutics' management efficiency ratios could be used to measure how well Chinook Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Chinook Therapeutics currently holds 39.44 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Chinook Therapeutics has a current ratio of 12.35, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Chinook Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Ashish MBAVaxcyte
53
Marvin CaruthersViridian Therapeutics
85
CFA CFATravere Therapeutics
40
Birgitte MDAscendis Pharma AS
62
Craig MuirPliant Therapeutics
N/A
Jeff KnightCrinetics Pharmaceuticals
54
Teresa McCarthyAvidity Biosciences
61
Michael MBAArcellx
N/A
Frank McCormickAvidity Biosciences
75
John McKuneKalvista Pharmaceuticals
48
Kevan ShokatRevolution Medicines
N/A
Daniel PichlSpringWorks Therapeutics
42
Kristian MBAViridian Therapeutics
49
Michael LLMAscendis Pharma AS
54
Mike OuimettePliant Therapeutics
51
Kate AikenArcellx
N/A
Carrie MBAViridian Therapeutics
N/A
Mike PreighDay One Biopharmaceuticals
N/A
Margaret JDRevolution Medicines
62
MBA MDViridian Therapeutics
72
Stephen MDKura Oncology
53
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. Chinook Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 138 people. Chinook Therapeutics (KDNY) is traded on NASDAQ Exchange in USA and employs 214 people.

Management Performance

Chinook Therapeutics Leadership Team

Elected by the shareholders, the Chinook Therapeutics' board of directors comprises two types of representatives: Chinook Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chinook. The board's role is to monitor Chinook Therapeutics' management team and ensure that shareholders' interests are well served. Chinook Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chinook Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Tom Frohlich, Chief Officer
Jodi Jamieson, VP HR
MS MD, Sr Strategy
Eric MBA, Chief Officer
Kirk JD, Sr Counsel
Alan MD, Ex Officer
Andrew DVM, Chief Officer
Eric JD, CEO Pres
Noopur Liffick, VP Communications
Delphine Imbert, VP Operations

Chinook Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chinook Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Consideration for investing in Chinook Stock

If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world